American pharmaceutical giant Johnson and Johnson is increasingly relying on artificial intelligence to significantly reduce the time required to research and develop new treatments, at a time when the pharmaceutical industry is looking for solutions to shorten extremely expensive and time-consuming processes. According to the company and #39;s IT director, Jim Swanson, quoted by Reuters, AI has already managed to halve the time required to identify promising leads for the development of new drugs.

Continuarea pe: Bursa